Introduction {#s1}
============

Versican/PG-M is a type of large chondroitin sulfate proteoglycan belonging to the aggrecan family, and plays important roles in cell adhesion, migration and differentiation as a molecule of extracellular matrix (ECM).[@R1] Versican is first identified in culture medium of fibroblasts[@R5] and its wide-range distribution is subsequently revealed in the smooth muscle cells,[@R6] [@R7] cartilage,[@R8] skin[@R9] and blood vessels.[@R10] Versican is also expressed at the ECM of malignant tumors[@R11] [@R12] and developing embryos.[@R10] [@R13]

The main cell type that produces versican in inflammatory lesions has been revealed to be macrophages.[@R4] Many other reports also demonstrated that macrophages express versican and that it is overexpressed when they are activated by granulocyte-macrophage-colony-stimulating factor (GM-CSF),[@R14] lipopolysaccharide[@R15] and hypoxia.[@R16] At ECM, it binds to hyaluronan and other ECM molecules such as fibronectin[@R4] [@R17] and several chemokines,[@R18] [@R19] thereby influencing leucocyte function.

Versican reportedly exists in the long-term culture of mouse bone marrow (BM) cells[@R20] and in the ECM of BM after chemotherapy.[@R21] Moreover, Oguri *et al*[@R22] detected a large amount of proteoglycan with chondroitin 6-sulfate in rabbit BM tissues. Although versican in BM has not been analysed biochemically, proteoglycans at the ECM have been known as binding partners for humoral factors that activate haematopoietic progenitors.[@R23] These reports support the hypothesis that versican may play an important role in the haematopoiesis of BM. Localisation of versican in BM tissue has been analysed immunohistochemically, yet the cells that produce versican in this tissue were not delineated.

Transplantation of cord blood (CB), BM and peripheral blood (PB) stem cells (SCs) has been performed for treatment of haematopoietic diseases such as leukaemia. Down these lines, Nagasaka *et al*[@R21] showed that the versican level is increased in BM of patients who have undergone chemotherapy. Therefore, it is likely that versican in BM may positively influence haematopoiesis in tissue after transplantation. To date, no study has been conducted to elucidate versican\'s overexpression and role in transplanted BM.

The purpose of this study is to identify versican-producing cells in normal BM and to shed light on the significance of versican in transplanted BM.

Patients and methods {#s2}
====================

Patients {#s2a}
--------

To address the possible significance of versican in BM regeneration, we enrolled 18 patients with acute myelogenous leukaemia (AML) who underwent cord blood stem cell transplantation (CBSCT). As we obtained clot specimens from an AML case 3 times and from 3 AML cases 2 times, the total number of samples in the assessment was 23. Three different stem cell transplantation (SCT) procedures have been performed at our hospital, namely, CBSCT, BMSCT and PBSCT. CBSCT is our current standard procedure because the graft versus host defence is less pronounced with it, and only a part of human leucocytic antigens needs to be matched.[@R24] [@R25] Therefore, we confined our analysis to CBSCT-treated patients. Our preparative regimen for CBSCT was based on previous reports, which was recently summarised by Arai *et al*[@R26] and was shown in [table 1](#JCLINPATH2015203496TB1){ref-type="table"}.

###### 

General conditioning regimen before and after transplantation of our hospital

  Day   −7    −6    −5   −4   −3   −2   −1           0                  +1    +3    +6    +7
  ----- ----- ----- ---- ---- ---- ---- ------------ ------------------ ----- ----- ----- -------
        TBI   TBI   CA   CA   CY   CY   Tacrolimus   Transplantation    MTX   MTX   MTX   G-CSF
                                                     2.4±0.5×10^7^/kg                     

CA, cytarabine; CY, cyclophosphamide; G-CSF, granulocyte-colony stimulating factor; MTX, methotrexate; TBI, total body irradiation.

BM clot was collected from the +16 to +55 day after transplantation for routine cytological and pathological evaluation of engraftment. We separated patients into four groups based on the duration after transplantation as follows: 16--25, 26--35, 36--45 and 46--55 days. We included a case, whose specimen was obtained at the +9 day to examine a cause of his high fever, because it likely shows a possible tendency of the number of versican-positive/CD68-positive macrophages in the early phase of the recovery. The breakdown of these samples is shown in [table 2](#JCLINPATH2015203496TB2){ref-type="table"}.

###### 

Clinical data of patients enrolled in this study

  Case no.    Group                                Days     Age      Sex   Diagnosis
  ----------- ------------------------------------ -------- -------- ----- -----------------
  1                                                9        58       M     MDS/AML
  2           16--25                               20       40       M     AML
  3                                                22       59       F     MDS/AML
  4                                                23       57       F     AML
  5                                                25       34       F     AML
                                                   23±2\*   48±12†         
  6           26--35                               28       37       M     AML
  7                                                28       49       F     AML
  8                                                29       43       F     AML
  9                                                29       54       M     AML
  10                                               33       44       M     AML
  11                                               34       55       M     MDS/AML
                                                   30±3\*   47±7†          
  12          36--45                               36       27       F     AML
  13                                               36       55       M     AML
  14                                               36       59       M     MDS/AML
  [15]{.ul}                                        36       60       F     MDS/AML
  [16]{.ul}                                        38       57       F     AML
  17                                               40       54       M     AML
  18                                               41       55       F     AML
  19                                               42       30       M     AML
                                                   38±3\*   50±13†         
  [20]{.ul}   46--55                               50       54       M     AML
  [21]{.ul}                                        52       40       M     AML
  22                                               55       49       F     AML
  [23]{.ul}                                        55       58       F     AML
                                                   53±2\*   50±8†          
              Age-matched poor engraftment group                           
  1           Poor                                 20       30       M     AML
  2                                                21       31       F     AML
  3                                                26       55       M     AML
  4                                                34       49       F     AML
                                                   25±6\*   41±13†         
              Age-matched normocellular group                              
  1                                                         20       F     Nephrosis
  2                                                         27       F     Lymphadenitis
  3                                                         37       M     Lymphadenitis
  4                                                         52       M     Hyperthyroidism
  5                                                         68       M     Amyloidosis
  6                                                         75       M     COPD
  7                                                         86       F     Lymphadenitis
                                                            52±25†         

Patients were grouped based on the day their clots were sampled. The mean age of each group was not significantly different.

\*Indicates the average days and SD after CBSCT in each group. Underlines indicate patients whose bone marrow specimens were obtained multiple times.

†Indicates the average age and SD in each group.

AML, acute myelogenous leukaemia; CBSCT, cord blood stem cell transplantation; COPD, chronic obstructive pulmonary disease; days, sampling days; F, female; M, male; MDS/AML, myelodysplastic syndrome overt AML.

According to the record, no patients experienced recurrence. We identified four other patients with AML who exhibited severe hypocellularity in BM about 3--5 weeks after CBSCT, likely showing engraftment failure. We analysed this age-matched poor engraftment group in the same way and compared with the corresponding 16--25 and 26--35 groups (namely, age-matched and sampling day-matched control). To determine versican-expressing cells in BM, we selected seven patients whose BM was isolated for diagnostic purpose and was normocellular, and then clinicopathologically diagnosed not to have haematological and other significant diseases. We named this an age-matched normocellular group ([table 1](#JCLINPATH2015203496TB1){ref-type="table"}) and the numbers of the total cells, and versican-positive and CD68-positive cells were used as a baseline for the kinetics assessment. Informed consent was obtained from each patient and the protocol was approved by the ethical committee of Nagoya University.

Immunohistochemistry {#s2b}
--------------------

All samples used in this study were formalin-fixed and paraffin-embedded. Several 4 μm-thick sections were cut from the paraffin blocks, and one was stained with H&E for diagnostic purposes. In immunohistochemistry (IHC), antigen-bound antibodies were visualised using a kit (Bond Polymer Refine Detection, Leica Biosystems Newcastle, UK), and brown colour was developed with diaminobenzidine (DAB).

Since versican-expressing cells were found likely to be macrophages, we performed double IHC using antibodies to versican (Abcam, Cambridge, UK) and to CD68 (PG-M1; Dako, Glostrup, Denmark). We employed this CD68 antibody because it was used to label all macrophages in BM.[@R27] With this technique, after versican-bound antibody was visualised with a brown colour with DAB, anti-CD68 antibody was reacted to the tissue section, and coloured red using the Bond Polymer Refine Red Detection kit (Leica Biosystems, Newcastle, UK). Nuclei were counterstained by haematoxylin, and immunohistochemical stain was carried out by the automatic IHC device (Leica BOND-MAX, Leica Biosystems).

Statistical analysis {#s2c}
--------------------

All BM samples were divided into four groups based on duration after transplantation, 16--25, 26--35, 36--45 and 46--55 days ([table 2](#JCLINPATH2015203496TB2){ref-type="table"}). After immunostaining, all cells, versican-positive cells and CD68-positive cells in a 0.15 mm^2^ area of several sections were counted, and the average number and SD of each group were obtained. These data were compared with either each other or those of the age-matched normocellular group (analysis of variance, Bonferroni\'s correction). Data of the age-matched poor engraftment group were compared with those from the age-matched and sampling day-matched control (Student\'s t test). We used a Stat View program (STAT View for Windows, V.5; SAS Institute, Cary, New Castle, USA) and significance was set at p\<0.05.

Results {#s3}
=======

Macrophages are the versican-producing cells in BM {#s3a}
--------------------------------------------------

We selected patients who had no haematopoietic or significant systemic diseases for this purpose ([table 2](#JCLINPATH2015203496TB2){ref-type="table"}, age-matched normocellular group, [figure 1](#JCLINPATH2015203496F1){ref-type="fig"}A). Results of the single ([figure 1](#JCLINPATH2015203496F1){ref-type="fig"}B, C) as well as double ([figure 1](#JCLINPATH2015203496F1){ref-type="fig"}D) IHC on BM clot samples with anti-versican and anti-CD68 antibodies strongly supported the consideration that versican is produced, partially if not entirely, by macrophages residing at the tissue stroma.

![Determination of versican-expressing cells in bone marrow specimens. (A) H&E stain. (B and C) Immunohistochemical stain with anti-versican (B) and anti-CD68 (C) antibodies, respectively, in the same bone marrow tissue. (D) Double immunohistochemical stain with anti-versican together with the anti-CD68 antibodies in bone marrow tissue. The most versican-positive cells (brown colour) are also CD68-positive (red colour) (open arrows). Nuclei were counterstained with haematoxylin. Original magnification for 3A--3D: ×1000.](jclinpath-2015-203496f01){#JCLINPATH2015203496F1}

Kinetics of versican-producing macrophages in repopulating BM after CBSCT {#s3b}
-------------------------------------------------------------------------

Average numbers and SD of total cells, versican-positive cells and CD68-positive cells at the unit area in clots from the age-matched normocellular group were approximately 221, 6 and 13 cells/0.15 mm^2^, respectively ([figure 2](#JCLINPATH2015203496F2){ref-type="fig"}A--C, dotted horizontal bars). Then, BM clots of patients who underwent CBSCT were stained similarly and the total cells were counted and compared with those of this group ([figure 2](#JCLINPATH2015203496F2){ref-type="fig"}A--C, closed marks). The total haematopoietic cells in BM after pretreatment and transplantation appeared to be decreased on the +9 day ([figure 2](#JCLINPATH2015203496F2){ref-type="fig"}A) and recovered in number already for the 16--25 day group. Though not statistically significant, the total cell number kept gradually increasing thereafter ([figure 2](#JCLINPATH2015203496F2){ref-type="fig"}A). A significant increase in the total cell number was observed for the 46--55 day group compared with the 16--25 day group (\*p\<0.05). On the contrary, the average number of versican-positive cells increased steeply in the 16--25 group to that of the age-matched normocellular group (^\#\#\#^p\<0.001, [figure 2](#JCLINPATH2015203496F2){ref-type="fig"}B), and then sharply decreased (\*\*p\<0.01, \*\*\*p\<0.001, [figure 2](#JCLINPATH2015203496F2){ref-type="fig"}B) when the total cell number increased. The number of CD68-positive macrophages was unaltered for the first month but fell significantly to the age-matched normocellular group in the 36--45 day group (^\#\#^p\<0.01, [figure 2](#JCLINPATH2015203496F2){ref-type="fig"}C). The linearly regressed time-course curves of the number of the total and versican-positive cells are schematically shown in [figure 2](#JCLINPATH2015203496F2){ref-type="fig"}D, demonstrating their inverse relationship over the examined period.

![The average numbers and SD of the total (A), versican-positive (B) and CD68-positive cells (C) in a 0.15 mm^2^ area of bone marrow tissues. The dotted horizontal bars are an average of total, versican-positive and CD68-positive cells from the age-matched normocellular group. (A) \*Indicates a significant difference between the 16--25 day and 46--55 day groups (analysis of variance, \*p\<0.05). Data were linearly well regressed (r^2^=0.962). (B) ^\#\#\#^Indicates a significant difference between the 16 and 25 day and the age-matched normocellular groups (^\#\#\#^p\<0.001). \*\* and \*\*\* indicate a significant difference between the 16 and 25 day group and other three groups (\*\*p\<0.01, \*\*\*p\<0.001). Linear regression was applied as in (A) (r^2^=0.282). (C) ^\#\#^ and \* indicate a significant difference between the 36 and 45 day group and the age-matched normocellular group (^\#\#^p\<0.01) or 16--25 day group (\*p\<0.05), respectively. A polynomial curve was well regressed (r^2^=0.974). (D) A schematic presentation of the versican-positive macrophage (closed line) in reference to the total cells (dotted line). Their corresponding baselines from the age-matched normocellular group were overlayered.](jclinpath-2015-203496f02){#JCLINPATH2015203496F2}

Comparison of the poor engraftment group {#s3c}
----------------------------------------

The total cell number of the BM in the age-matched poor engraftment group was approximately six times less than that of the control (\*\*\*p\<0.001, [figure 3](#JCLINPATH2015203496F3){ref-type="fig"}A). The number of versican-positive cells appeared to be less than half that of the age-matched and sampling day-matched control, yet it did not reach statistical significance (p=0.056, [figure 3](#JCLINPATH2015203496F3){ref-type="fig"}B). Meanwhile, the CD68-positive cell number seemed unaltered between the poor and the control groups ([figure 3](#JCLINPATH2015203496F3){ref-type="fig"}B).

![Comparison of the total cell numbers (A), versican-positive (B, left) and CD68-positive cells (B, right) of the age-matched and sampling day-matched patients group (open bar) with those of the age-matched poor engraftment group (closed bar). \*Indicates a significant difference (t test, \*\*\*p\<0.001). Versican-positive macrophages are approximately half that of the control, yet it does not reach statistical significance (p=0.056).](jclinpath-2015-203496f03){#JCLINPATH2015203496F3}

Discussion {#s4}
==========

Versican is an ECM molecule known to play an important role in cell adhesion, motility and immobilisation of humoral molecules.[@R2] [@R18] [@R28] Moreover, versican participates intimately in the process of human diseases such as inflammation, atherosclerosis, cardiac infarction, and proliferation and invasion of cancer cells.[@R2] [@R4] [@R28] Versican is a significant ECM molecule as mentioned; hence, it is important to determine the type of versican-producing cells that are active at ECM of various normal and diseased tissues.

Several reports demonstrated that monocytes and macrophages,[@R4] [@R14] [@R15] [@R16] [@R29] [@R30] inflammatory cells,[@R4] fibroblasts[@R31] and myofibroblasts[@R32] express versican. In many normal and disease tissues, however, cells that express versican are still not well established. Moreover, no reports so far have examined the cells in BM, which is known to contain versican.[@R21] These facts prompted us to delineate cell types that produce versican in BM, while paying particular attention to tissue macrophages (see above). Using the single IHC method, we first stained the normocellular BM and observed that the anti-versican antibody appears to label macrophages. Then, applying double IHC using anti-versican and CD68 antibodies, we stained the same tissues and concluded that the major versican-expressing cells in BM are macrophages.

Macrophages are important players in the process of various diseases such as atherosclerosis, pneumonia, infectious diseases and progression of cancers.[@R4] Moreover, macrophages are known to play an important role in BM regeneration.[@R33] Meanwhile, versican functions as an important scaffold ECM molecule, and the haematopoietic restoration in transplanted BM appears to be regulated by proteoglycans of ECM and humoral factors.[@R23] Therefore, we hypothesised that macrophage-derived versican may contribute to the regeneration process of BM after SCT for haematopoietic diseases.

Haematopoietic SCTs, BM, PB and CBSCT are performed as treatments for haematolymphoid neoplastic diseases including leukaemias and lymphomas.[@R38] Clinically, cytarabine (CA)+cyclophosphamide (CY)+total body irradiation (TBI) (CA+CY+TBI) is generally performed in these transplantations as pretreatment to kill neoplastic cells as well as patients' haematopoietic cells[@R26] [@R39] and for the first few weeks, the total cell number in the BM declines. Then, blood SCs from donors are transfused to patients, engrafted and then start to produce progenitors such as neutrophils. They finally appear in PB, increase for 2--3 weeks and reach the normal level after approximately 40 days. An engraftment is defined by the number of neutrophils in the PB, which should be more than 500/μL for three continuous days.

We observed that around 10 days after transplantation the total number of haematopoietic cells in our patients' BM lowered to the minimum and recovered in number after 3--4 weeks, just as mentioned above. On the contrary, the number of versican-positive macrophages was sharply increased for 3 weeks, and then declined thereafter. This result demonstrated an inverse time course of the versican-positive macrophages to that of total cells in the transplanted BM. Meanwhile, the number of CD68-positive macrophages remained unaltered for the first 3 weeks unlike that of versican-positive macrophages, suggesting that not all macrophages but the versican-expressing ones play an important role in regeneration in this period. Given that versican contributes to BM regeneration in a positive fashion, it would be expected that the number of versican-positive macrophages in BM of the poor engraftment cases is lower than that of fine engraftment cases. Although not statistically significant, we observed a clear trend of lowered versican-positive cells in their BM. It requires more such cases in future. Macrophages are known to exist as resident cells in a steady state of BM.[@R27] It seems that residential macrophages, which are at first negative in versican expression, become versican-positive for the 3 weeks after transplantation. Perhaps the versican-negative/CD68-positive macrophages start to express versican when BM is damaged by preconditioning and SCs are engrafted. In BM of multiple myeloma patients, after allogenic SCT, it becomes rich in chemokines and other humoral factors.[@R40] Interestingly, versican can activate macrophages to upregulate tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6).[@R41] At least, in neuronal cells TNF-α induces versican expression.[@R42] Perhaps, after preconditioning and CBSCT in BM, a positive feedback loop between versican and macrophage would be in function.

Although the underlying mechanism behind versican\'s contribution to BM regeneration is not clear, given that versican serves as a scaffold molecule that binds several serological factors such as chemokines[@R18] and midkines,[@R19] it is likely that versican at the BM stroma binds humoral factors such as granulocyte-colony-stimulating factor. In fact, in our hospital and in many others, it is perfused on the +7 day of transplantation to aid progenitors so as to be differentiated into neutrophils.

Another intriguing unsolved question is the origin of macrophages after CBSCT. Given that versican presets a favourable environment in the BM for donors' SCs, they should not be eliminated by preconditioning. Comparison of BM clots just before and after preconditioning will be essential to determine the hypothesis above. The use of sex-determining in situ hybridisation on the clot specimens of patients who received CBSCT from sex-unmatched donor should also be performed in future.

In this report, we demonstrated that the predominant versican-expressing cells in BM are macrophages, and evaluated a time course of the number of versican-positive macrophages in BM after CBSCT. Our results suggest that versican and/or versican-expressing macrophages have important roles in BM regeneration by establishing a supportive environment at its ECM for transplanted SCs to be engrafted. We are preparing several more cases of AML with CBSCT and will analyse them in the near future. Moreover, in vivo and in vitro experiments on versican induction in macrophages of BM should further be performed to establish the present analysis on human samples.

###### Take home messages

-   Versican is produced by macrophages in bone marrow as in many other tissues.

-   In bone marrow of patients with acute myelogenous leukaemia after cord blood stem cell transplantation (CBSCT), the number of versican-positive macrophages is inversely correlated to that of total cells.

-   Versican seems to play an important role in bone marrow regeneration after CBSCT.

Supplementary Material
======================
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